GleamWall
中文EN

OKYO OKYO Pharma Ltd IFRS Annual reports only

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1849296

Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY72.0%
TTM EPS YoY64.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-180.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets250.9%
Debt / equity—
Current ratio0.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio-111.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY2025*2025-03-31FY2024*2024-03-31
Income statement
Revenue——
R&D expense$2.25M$8.24M
Interest expense$878,174$1.05M
Pretax income-$7.97M-$16.80M
Income tax$3.26M-$22,416
Net income-$4.71M-$16.83M
EPS (basic)-0.20-0.57
EPS (diluted)-0.20-0.57
Balance sheet
Cash & equivalents$1.56M$826,848
Current assets$3.68M$1.54M
PP&E, netmay include right-of-use assets (IFRS)$2,035$3,350
Total assets$3.68M$1.54M
Current liabilities$9.23M$7.42M
Short-term debt$2.70M—
Total liabilities$9.23M$7.42M
Shareholders' equity-$5.55M-$5.88M
Cash flow statement
Operating cash flow-$1.81M-$9.49M
Capital expenditure$1,208—
Free cash flow-$1.81M—
Investing cash flow-$1,208—
Financing cash flow$2.66M$6.21M
Depreciation & amortization$2,563$3,866
Stock-based compensation$734,989$1.12M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.